Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights FDA Approval of Emrosi ( 40 mg Minocycline Hydrochloride Modified-Release Capsules ) for Rosacea Emrosi Initial Distrib

Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

of Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea

Distribution Ongoing; First Prescriptions Filled

for the Full Year Ended December 31, 2024 were $56.1 million

3 Clinical Trial Results Published in JAMA Dermatology

Conference Call Today at 4:30 p.m. ET

AZ - March 26, 2025 - Journey Medical Corporation (Nasdaq: DERM) ("Journey Medical" or "the Company",

"we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing

of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological

conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2024.

Journey Medical's Co-Founder, President and Chief Executive Officer, said, "We delivered a solid performance in 2024, meeting

all of our financial guidance ranges and received first cycle FDA approval for Emrosi in November, ahead of the scheduled PDUFA

date. Emrosi's superb Phase 3 clinical results demonstrated its best-in-class profile, and we expect it will become the standard

of care and transform our business. Our cash position remains strong ahead of Emrosi's launch and our objective is to deliver enhanced

revenue growth and become sustainably EBITDA positive. I am pleased to report that we have begun distribution of Emrosi, that first prescriptions

have been dispensed and that we continue to execute ahead of schedule, with full promotion expected in April 2025."

and Webcast Information

management will conduct a conference call and audio webcast on March 26, 2025, at 4:30 p.m. ET.

conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers

should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Journey Medical conference call.

Participants can register for the conference here: https://dpregister.com/sreg/10197674/feaf5b7354. Please note that registered participants

will receive their dial-in number upon registration.

A live audio webcast

can be accessed on the News and Events page of the Investors section of Journey Medical's website, www.journeymedicalcorp.com,

and will remain available for replay for approximately 30 days after the meeting.

is a registered trademark of Galderma Holdings, S.A. Soci t Anonyme.

Corporation (Nasdaq: DERM) ("Journey Medical") is a commercial-stage pharmaceutical company that primarily focuses on the

selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its

efficient sales and marketing model. The Company currently markets eight FDA approved prescription drugs that help treat and heal common

skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some

of dermatology's most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress

Biotech, Inc. (Nasdaq: FBIO). Journey Medical's common stock is registered under the Securities Exchange Act of 1934, as amended,

and it files periodic reports with the U.S. Securities and Exchange Commission ("SEC"). For additional information about

Journey Medical, visit www.journeymedicalcorp.com.

may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and

Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words "the

Company", "we", "us" and "our" may refer to Journey Medical. Such statements include, but are

not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not

historical facts. The words "anticipate," "believe," "estimate," "may," "expect,"

"will," "could," "project," "intend," "potential" and similar expressions

are generally intended to identify forward-looking statements. Forward-looking statements are based on management's current expectations

and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock

price. Factors that could cause actual results to differ materially from those currently anticipated include: the fact that our products

and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully

developed or commercialized; a substantial portion of our sales derive from products that may become subject to third-party generic competition,

the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have

a significant adverse impact on our operating income; we operate in a heavily regulated industry, and we cannot predict the impact that

any future legislation or administrative or executive action may have on our operations; our revenue is dependent mainly upon sales of

our dermatology products and any setback relating to the sale of such products could impair our operating results; competition could

limit our products' commercial opportunity and profitability, including competition from manufacturers of generic versions of our

products; the risk that our products do not achieve broad market acceptance, including by government and third-party payors; our reliance

third parties for several aspects of our operations; our dependence on our ability to identify, develop, and acquire or in-license products

and integrate them into our operations, at which we may be unsuccessful; the dependence of the success of our business, including our

ability to finance our company and generate additional revenue, on the successful commercialization of our recently approved product,

EmrosiTM, and any future product candidates that we may develop, in-license or acquire; clinical drug development is very

expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current

or any future product candidates; our competitors could develop and commercialize products similar or identical to ours; risks related

to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology

and products; our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our

or our third parties' cybersecurity; the substantial doubt about our ability to continue as a going concern; the effects of major

public health issues, epidemics or pandemics on our product revenues and any future clinical trials; our potential need to raise additional

capital; Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders; as well as other

risks described in Part I, Item 1A, "Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, 2024,

subsequent Reports on Form 10-Q, and our other filings we make with the SEC. We expressly disclaim any obligation or undertaking to release

publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any

changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the

protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Media Relations Contact:

except for share and per share amounts)

Statements of Operations

in thousands except for share and per share amounts)

Use of Non-GAAP Measures:

the GAAP financial measures as presented in our Form 10-K that will be filed with the Securities and Exchange Commission ("SEC"),

the Company has, in this press release, included certain non-GAAP measurements, including Adjusted EBITDA, Adjusted EBITDA per share

basic and Adjusted EBITDA per share diluted. We define Adjusted EBITDA as net income (loss) excluding interest, taxes and depreciation

and amortization, less certain other non-cash and infrequent items not considered to be normal, recurring operating expenses, including,

share-based compensation expense, amortization and impairments of acquired intangible assets, severance, short-term research and development

expense and foreign exchange transaction losses. In particular, we exclude the following matters for the reasons more fully described

per share basic and Adjusted EBITDA per share diluted are determined by dividing the resulting Adjusted EBITDA by the number of shares

outstanding on an actual and fully diluted basis.

the use of these non-GAAP measures provide meaningful supplemental information regarding the Company's performance because (i)

it allows for greater transparency with respect to key measures used by management in its financial and operational decision-making,

(ii) it excludes the impact of non-cash or, when specified, non-recurring items that are not directly attributable to the Company's

core operating performance and that may obscure trends in the Company's core operating performance and (iii) it is used by institutional

investors and the analyst community to help analyze the Company's results. However, Adjusted EBITDA, Adjusted EBITDA per share basic,

Adjusted EBITDA per share diluted and any other non-GAAP financial measures should be considered as a supplement to, and not as a substitute

for, or superior to, the corresponding measures calculated in accordance with GAAP. Further, non-GAAP financial measures used by the

Company and the manner in which they are calculated may differ from the non-GAAP financial measures or the calculations of the same non-GAAP

financial measures used by other companies, including the Company's competitors.

provides a reconciliation from GAAP to non-GAAP measures:

of GAAP to Non-GAAP Adjusted EBITDA

except for share and per share amounts)